Sophie J. Bradley

DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs<i>in Vitro</i>and<i>in Vivo</i>

Karen Thompson, Elham Khajehali, Sophie J. Bradley et al. · ACS Pharmacology & Translational Science · 2018 · 185 citations · Full text

From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

Alastair Brown, Sophie J. Bradley, Fiona H. Marshall et al. · Cell · 2021 · 87 citations · Full text

Molecular Pharmacology, Neurodegenerative Diseases, Alzheimer's Disease +10

M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss

Sophie J. Bradley, Julie-Myrtille Bourgognon, Helen Sanger et al. · Journal of Clinical Investigation · 2016 · 78 citations · Full text

Neurodegenerative Diseases, Alzheimer's Disease, Cholinergic Transmission +13

Chemogenetics defines receptor-mediated functions of short chain free fatty acids

Daniele Bolognini, Natasja Barki, Adrian J. Butcher et al. · Nature Chemical Biology · 2019 · 70 citations · Full text

Metabolic Syndrome, Signal Transduction, Biochemistry +5

Clustered Coding Variants in the Glutamate Receptor Complexes of Individuals with Schizophrenia and Bipolar Disorder

René Frank, Allan F. McRae, Andrew Pocklington et al. · PLoS ONE · 2011 · 64 citations · Full text

Genetics, Genetic Epidemiology, Neuropsychiatry +22